ProCE Banner Activity

Enasidenib Active, Well Tolerated in Small Cohort of MDS Patients With IDH2 Mutation

Slideset Download
Conference Coverage
Daily oral enasidenib monotherapy shows activity in a small cohort of patients with predominately high-risk mIDH2 MDS, including some who failed prior HMA treatment.

Released: December 06, 2016

Expiration: December 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen